Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD.
Dautzenberg
Paul L J
PL
Wouters
Cees J
CJ
Bootsma
Janet E M
JE
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D001519:Behavior / Q000187:drug effects*; D017028:Caregivers; D003071:Cognition / Q000187:drug effects*; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D008559:Memantine / Q000009:adverse effects / Q000627:therapeutic use*; D008609:Mental Status Schedule; D010045:Outpatients; D010352:Patient Dropouts / Q000706:statistics & numerical data; D016896:Treatment Outcome
D015259:Dopamine Agents; D008559:Memantine